Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03946072 · ClinicalTrials.gov registry record · NA
Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 153
- Enrollment target
NCT03946072: Completed NA study, sponsored by University of California, San Francisco.
NCT03946072 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 153 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03946072, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs).
Primary Outcome
incidence of new cerebral embolic lesions measured by magnetic resonance imaging (MRI) post-ablation as compared to pre-ablation imaging studies
Interventions
- PROCEDURE Transseptal Aortic Approach Catheter Ablation Procedure
- PROCEDURE Retrograde Aortic Approach Catheter Ablation Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2023-11-25 |
| Phase | NA |
What the finished NCT03946072 record still lists
NCT03946072 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Transseptal Aortic Approach Catheter Ablation Procedure is the first listed.
NCT03946072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03946072 about?
NCT03946072 is a clinical study titled "Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli". This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/...
What is the current status of trial NCT03946072?
This trial is currently completed. It is a NA study. The enrollment target is 153 participants. The study started on 2019-07-02. Estimated completion is 2023-11-25.
What interventions are being tested in trial NCT03946072?
The interventions under investigation include: Transseptal Aortic Approach Catheter Ablation Procedure (PROCEDURE), Retrograde Aortic Approach Catheter Ablation Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT03946072?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03946072's enrollment target sits among peer trials
153 656th of 2000 higher than 1,343 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI